Decreased_VBN insulin_NN binding_VBG to_TO mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS from_IN dogs_NNS after_IN S-Nitroso-N-Acetypenicillamine_NP administration_NN Abstract_NP |_SYM Background_NN |_SYM Nitric_JJ oxide_NN (_( NO_NP )_) and_CC oxygen_NN free-radicals_NNS play_VBP an_DT important_JJ part_NN in_IN the_DT destruction_NN of_IN beta-cells_NNS in_IN auto-_NN immune_JJ diabetes_NN although_IN the_DT precise_JJ mechanism_NN of_IN interaction_NN is_VBZ still_RB not_RB known_VBN ._SENT This_DT study_NN was_VBD designed_VBN to_TO examine_VB any_DT possible_JJ diabetogenic_JJ effect_NN of_IN NO_NP by_IN investigating_VBG any_DT differences_NNS in_IN cellular_JJ binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS of_IN dogs_NNS treated_VBN with_IN the_DT NO_NP donor_NN ,_, S-nitroso-N-acetylpenicillamine_NP (_( SNAP_NP )_) and_CC controls_NNS treated_VBN with_IN captopril_NP ._SENT Results_NNS |_SYM The_DT result_NN obtained_VBN showed_VBD decreased_VBN binding_VBG of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS ._SENT Mononuclear_JJ leucocytes_NNS from_IN SNAP-treated_JJ dogs_NNS had_VBD decreased_VBN ability_NN to_TO bind_NN insulin_NN (_( 16.30_CD +-_NN 1.24_CD %_NN )_) when_WRB compared_VBN to_TO mononuclear_JJ leucocytes_NNS from_IN captopril-treated_JJ controls_NNS (_( 20.30_CD +-_NN 1.93_CD %_NN )_) ._SENT Similar_JJ results_NNS were_VBD obtained_VBN for_IN erythrocytes_NNS from_IN dogs_NNS treated_VBN with_IN SNAP_NP (_( 27.20_CD +-_NN 1.33_CD %_NN )_) compared_VBN with_IN dogs_NNS treated_VBN with_IN captopril_NP (_( 34.70_CD +-_NN 3.58_CD %_NN )_) ._SENT Scatchard_NP analysis_NN demonstrated_VBD that_IN this_DT decrease_NN in_IN insulin_NN binding_NN was_VBD accounted_VBN for_IN by_IN a_DT decrease_NN in_IN insulin_NN receptor_NN sites_NNS per_IN cell_NN ,_, with_IN mononuclear_JJ leucocytes_NNS of_IN SNAP-treated_JJ dogs_NNS having_VBG 55_CD %_NN less_JJR insulin_NN receptor_NN sites_NNS per_IN cell_NN compared_VBN with_IN those_DT of_IN captopril-treated_JJ controls_NNS (_( P_NN <_SYM 0.05_CD )_) ._SENT Average_JJ affinity_NN and_CC kinetic_JJ analysis_NN revealed_VBD a_DT 35_CD %_NN decrease_NN in_IN the_DT average_JJ receptor_NN affinity_NN ,_, with_IN mononuclear_JJ leucocytes_NNS from_IN captopril-treated_JJ controls_NNS having_VBG an_DT empty_JJ site_NN affinity_NN of_IN 12.36_CD +-_NN 1.12_CD x_SYM 10-8_CD M-1_NN compared_VBN with_IN 9.64_CD +-_NN 0.11_CD x_SYM 10-8_CD M-1_NN in_IN SNAP-treated_JJ dogs_NNS (_( P_NN <_SYM 0.05_CD )_) ._SENT Conclusion_NN |_SYM These_DT results_NNS suggest_VBP that_IN acute_JJ alteration_NN of_IN the_DT insulin_NN receptor_NN on_IN the_DT membranes_NNS of_IN mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS occurred_VBN in_IN dogs_NNS treated_VBN with_IN S-nitroso-N-acetylpenicillamine_NP ._SENT These_DT findings_NNS suggest_VBP the_DT first_JJ evidence_NN of_IN the_DT novel_JJ role_NN of_IN NO_NP as_IN a_DT modulator_NN of_IN insulin_NN binding_NN and_CC the_DT involvement_NN of_IN NO_NP in_IN the_DT aetiology_NN of_IN diabetes_NN mellitus_NN ._SENT Nitric_JJ oxide_NN (_( NO_NP )_) is_VBZ a_DT physiologically_RB important_JJ signal_NN molecule_NN regulating_VBG a_DT variety_NN of_IN biological_JJ functions_NNS such_JJ as_IN smooth_JJ muscle_NN relaxation_NN ,_, neurotransmission_NN ,_, and_CC immune_JJ processes_NNS ._SENT Excess_JJ induction_NN of_IN NO_NP ,_, however_RB ,_, has_VBZ also_RB been_VBN implicated_VBN as_IN a_DT cause_NN of_IN diverse_JJ pathological_JJ conditions_NNS such_JJ as_IN inflammation_NN ,_, neuro-degenerative_JJ diseases_NNS ,_, cardiovascular_JJ disorders_NNS ,_, and_CC possibly_RB cancer_NN ._SENT These_DT detrimental_JJ effects_NNS of_IN NO_NP have_VBP been_VBN attributed_VBN to_TO reactive_JJ nitrogen_NN species_NNS such_JJ as_IN oxides_NNS of_IN nitrogen_NN (_( NOx_NP )_) and_CC peroxynitrite_NN (_( ONOO-_NP )_) ,_, which_WDT are_VBP formed_VBN by_IN the_DT reaction_NN of_IN NO_NP with_IN oxygen_NN and_CC superoxide_NN respectively_RB ._SENT Reactive_JJ nitrogen_NN species_NNS can_MD oxidize_VB ,_, nitrate_NN ,_, and_CC nitrosate_NN bio-molecules_NNS such_JJ as_IN proteins_NNS ,_, DNA_NP ,_, and_CC lipids_NNS ,_, thus_RB altering_VBG their_PP$ functions_NNS ._SENT S-nitroso-N-acetylpenicillamine_NP has_VBZ been_VBN shown_VBN to_TO be_VB potent_JJ smooth_JJ muscle_NN relaxants_NNS in_IN a_DT variety_NN of_IN vascular_JJ smooth_JJ muscle_NN preparations_NNS ._SENT It_PP has_VBZ been_VBN shown_VBN to_TO produce_VB significant_JJ inhibition_NN of_IN spontaneous_JJ contractions_NNS in_IN myometrial_JJ strips_NNS from_IN oestrogen-primed_JJ ,_, and_CC progesterone-treated_JJ rats_NNS ._SENT The_DT relaxant_JJ effect_NN of_IN SNAP_NP was_VBD found_VBN to_TO be_VB exerted_VBN by_IN a_DT mechanism_NN independent_JJ of_IN cGMP_NN elevation_NN but_CC may_MD be_VB due_JJ to_TO the_DT activation_NN of_IN a_DT calcium-activated_JJ potassium_NN channel_NN ._SENT Experiments_NNS were_VBD also_RB done_VBN with_IN SNAP_NP ,_, to_TO validate_VB the_DT significance_NN of_IN NO_NP in_IN the_DT development_NN of_IN diabetes_NN ._SENT The_DT results_NNS showed_VBD cleavage_NN of_IN the_DT DNA_NN into_IN nucleosomal_JJ fragments_NNS ._SENT This_DT NO_NP donor_NN cause_VBP the_DT activation_NN of_IN poly(ADP_NN ribose_NN )_) synthase_NN in_IN cell_NN nuclei_NNS ,_, and_CC this_DT activation_NN depletes_VBZ intracellular_JJ NAD+_NN by_IN consuming_VBG it_PP as_IN its_PP$ substrate_NN ._SENT It_PP is_VBZ proposed_VBN that_IN internucleosomal_JJ DNA_NN cleavage_NN induced_VBN by_IN NO_NP activates_VBZ poly(ADP_NN ribose_NN )_) synthase_NN ,_, which_WDT in_IN turn_NN depletes_VBZ intracellular_JJ NAD+_NN and_CC causes_VBZ poly-ADP-ribosylation_NN of_IN nuclear_JJ proteins_NNS ,_, resulting_VBG in_IN the_DT deterioration_NN of_IN beta-cell_NN function_NN ._SENT Insulin_NN binding_VBG to_TO receptors_NNS is_VBZ the_DT first_JJ event_NN in_IN insulin_NN action_NN ,_, and_CC this_DT first_JJ step_NN represents_VBZ a_DT major_JJ control_NN point_NN for_IN insulin_NN 's_POS effects_NNS in_IN vivo_RB ._SENT Insulin_NN binding_VBG to_TO receptors_NNS is_VBZ not_RB a_DT fixed_VBN biologic_JJ process_NN ,_, but_CC is_VBZ subjected_VBN to_TO modulation_NN by_IN alterations_NNS in_IN either_DT receptor_NN number_NN or_CC affinity_NN ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP investigated_VBD the_DT acute_JJ effects_NNS of_IN a_DT dose_NN of_IN SNAP_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS and_CC whether_IN an_DT insulin-receptor_NN defect_NN is_VBZ of_IN importance_NN in_IN the_DT hyperglycemic_JJ condition_NN ._SENT Figure_NN and_CC Figure_NN summarizes_VBZ the_DT ability_NN of_IN non-radioactive_JJ insulin_NN to_TO competitively_RB inhibit_VB the_DT binding_NN of_IN 125-I-insulin_NP to_TO the_DT insulin_NN receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS respectively_RB ,_, in_IN dogs_NNS treated_VBN with_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, and_CC controls_NNS treated_VBN with_IN 20_CD mg/kg_NN of_IN captopril_NP or_CC 2_CD ml_NN of_IN DMSO_NP ._SENT Comparison_NN of_IN the_DT plots_NNS showed_VBD that_IN insulin_NN receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS from_IN dogs_NNS treated_VBN with_IN SNAP_NP binds_VBZ significantly_RB less_JJR 125-I-insulin_NN than_IN cells_NNS from_IN the_DT captopril-treated_JJ controls_NNS and_CC those_DT administered_VBN with_IN 2_CD ml_NN of_IN DMSO_NP at_IN unlabelled_JJ insulin_NN concentrations_NNS ._SENT Figure_NP 1_CD |_SYM Competitive_JJ binding_JJ curves_NNS showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN mononuclear_JJ leucocytes_NNS ._SENT Competitive_JJ binding_JJ curves_NNS showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN mononuclear_JJ leucocytes_NNS ._SENT Percentage_NN of_IN 125-I-insulin_NP ._SENT bound_VBN is_VBZ plotted_VBN as_IN a_DT function_NN of_IN the_DT unlabelled_JJ insulin_NN concentration_NN ._SENT Statistical_JJ significant_JJ differences_NNS are_VBP indicated_VBN by_IN *P_NP <_SYM 0.05_CD and_CC *P_NNS <_SYM 0.01_CD ._SENT Figure_NP 2_CD |_SYM Competitive_JJ binding_JJ curves_NNS showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS ._SENT Competitive_JJ binding_JJ curves_NNS showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS ._SENT Percentage_NN of_IN 125-I-insulin_NP ._SENT bound_VBN is_VBZ plotted_VBN as_IN a_DT function_NN of_IN the_DT unlabelled_JJ insulin_NN concentration_NN ._SENT Statistical_JJ significant_JJ differences_NNS are_VBP indicated_VBN by_IN *P_NP <_SYM 0.05_CD and_CC *P_NP <_0.01. 0.05_CD )_) ,_, with_IN the_DT exception_NN of_IN the_DT percentage_NN 125-I-insulin_NN bound_VBN at_IN 2.5_CD ng/ml_NNS (_( P_NN =_SYM 0.006_CD )_) ._SENT A_DT similar_JJ trend_NN was_VBD seen_VBN on_IN examination_NN of_IN the_DT erythrocytes_NNS binding_VBG profile_NN ._SENT The_DT maximum_JJ percentage_NN of_IN 125-I-insulin_NP bound_VBN to_TO the_DT insulin_NN receptor_NN using_VBG captopril_NP was_VBD 34.70_CD +-_NN 3.58_CD %_NN and_CC dogs_NNS administered_VBN with_IN DMSO_NP ,_, 32.60_CD +-_NN 4.67_CD %_NN compared_VBN with_IN 27.20_CD +-_NN 1.33_CD %_NN for_IN erythrocytes_NNS of_IN dogs_NNS with_IN SNAP_NP (_( P_NN >_SYM 0.05_CD )_) ._SENT Further_JJR analysis_NN showed_VBD that_IN the_DT percentage_NN of_IN 125-I-insulin_NP bound_VBN to_TO the_DT insulin_NN receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS of_IN SNAP-treated_JJ dogs_NNS at_IN unlabelled_JJ insulin_NN concentrations_NNS greater_JJR than_IN 0.5_CD ng/ml_NNS ,_, were_VBD appreciably_RB less_JJR and_CC statistically_RB significant_JJ than_IN those_DT of_IN the_DT captopril-treated_JJ controls_NNS (_( P_NN <_SYM 0.05_CD )_) ._SENT Comparison_NN of_IN the_DT competition_NN curves_VBZ of_IN percentage_NN 125-I-insulin_NN bound_VBN to_TO the_DT insulin_NN receptor_NN on_IN erythrocytes_NNS of_IN the_DT SNAP-treated_JJ dogs_NNS and_CC captopril-treated_JJ controls_NNS showed_VBD slopes_NNS that_WDT decreased_VBD steadily_RB to_TO values_NNS of_IN 15.45_CD +-_NN 1.02_CD %_NN and_CC 25.45_CD +-_NN 1.76_CD %_NN respectively_RB (_( P_NN =_SYM 0.007_CD )_) at_IN an_DT unlabelled_JJ insulin_NN concentration_NN of_IN 10_CD ng/ml_NNS ._SENT The_DT integrated_JJ area_NN under_IN the_DT curve_NN for_IN mononuclear_JJ leucocytes_NNS from_IN dogs_NNS treated_VBN with_IN 20_CD mg/kg_NN of_IN SNAP_NP was_VBD 88.65_CD +-_NN 5.28_CD %_NN x_SYM 10_CD ng/ml_NNS compared_VBN with_IN 131.76_CD +-_NN 5.57_CD %_NN x_SYM 10_CD ng/ml_NNS in_IN captopril-treated_JJ controls_NNS (_( P_NN <_SYM 0.05_CD )_) and_CC 126.65_CD +-_NN 4.3.28_CD %_NN in_IN dogs_NNS administered_VBN with_IN DMSO_NP ._SENT In_IN this_DT study_NN ,_, bound/free_JJ (_( B/F_NP )_) ratio_NN of_IN the_DT labelled_VBN hormone_NN is_VBZ expressed_VBN as_IN a_DT function_NN of_IN the_DT bound_JJ hormone_NN giving_VBG a_DT Scatchard_NP Plot_NP for_IN mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS ._SENT Curvilinear_JJ plots_NNS were_VBD obtained_VBN for_IN the_DT controls_NNS treated_VBN with_IN 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP ,_, and_CC dogs_NNS treated_VBN with_IN 20_CD mg/kg_NN of_IN SNAP_NP ._SENT A_DT greater_JJR B/F_NP implies_VBZ that_IN there_EX is_VBZ more_JJR bound_JJ hormone_NN than_IN free_JJ ._SENT Comparison_NN of_IN the_DT plots_NNS showed_VBD that_IN insulin_NN receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN mononuclear_JJ leucocytes_NNS for_IN captopril-treated_JJ controls_NNS and_CC dogs_NNS treated_VBN with_IN DMSO_NP had_VBD maximum_JJ B/F_NP values_NNS of_IN 0.221_CD +-_NN 0.03_CD and_CC 0.219_CD +-_NN 0.13_CD respectively_RB ,_, compared_VBN with_IN 0.182_CD +-_NN 0.01_CD for_IN SNAP-treated_JJ dogs_NNS at_IN the_DT 1.5_CD h_NN time_NN interval_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT Further_RBR statistical_JJ analysis_NN revealed_VBD that_IN although_IN the_DT B/F_NP 125-I-insulin_NP ratios_NNS for_IN the_DT SNAP-treated_JJ dogs_NNS were_VBD appreciably_RB less_JJR than_IN the_DT captopril-treated_JJ controls_NNS ,_, the_DT differences_NNS were_VBD only_RB statistically_RB significant_JJ at_IN an_DT unlabelled_JJ insulin_NN concentration_NN of_IN 10_CD ng/ml_NNS (_( P_NN =_SYM 0.017_CD )_) ._SENT Figure_NP 3_CD |_SYM Scatchard_NP plot_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN mononuclear_JJ leucocytes_NNS ._SENT Scatchard_NP plot_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN mononuclear_JJ leucocytes_NNS ._SENT Bound/Free_JJ ratio_NN is_VBZ plotted_VBN as_IN a_DT function_NN of_IN the_DT insulin_NN bound_VBN (_( B_NP )_) ._SENT Statistical_JJ significant_JJ differences_NNS are_VBP indicated_VBN by_IN *P_NP <_SYM 0.05_CD and_CC **P_NNS <_SYM 0.01_CD ._SENT Figure_NP 4_CD |_SYM Scatchard_NP plot_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS ._SENT Scatchard_NP plot_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS ._SENT Bound/Free_JJ ratio_NN is_VBZ plotted_VBN as_IN a_DT function_NN of_IN the_DT insulin_NN bound_VBN (_( B_NP )_) ._SENT Statistical_JJ significant_JJ differences_NNS are_VBP indicated_VBN by_IN *P_NP <_SYM 0.05_CD and_CC **P_NP <_0.01. 0.05_CD )_) ._SENT Figure_NP 5_CD |_SYM Average_JJ affinity_NN profile_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN mononuclear_JJ leucocytes_NNS ._SENT Average_JJ affinity_NN profile_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN mononuclear_JJ leucocytes_NNS ._SENT Average_JJ receptor_NN affinity_NN is_VBZ plotted_VBN as_IN a_DT function_NN of_IN the_DT receptor_NN occupancy_NN ._SENT Figure_NP 6_CD |_SYM Average_JJ affinity_NN profile_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS ._SENT Average_JJ affinity_NN profile_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS ._SENT Average_JJ receptor_NN affinity_NN is_VBZ plotted_VBN as_IN a_DT function_NN of_IN the_DT receptor_NN occupancy_NN ._SENT Analysis_NN of_IN the_DT data_NN shows_VBZ that_IN mononuclear_JJ leucocytes_NNS of_IN dogs_NNS treated_VBN with_IN captopril_NP have_VBP an_DT '_'' empty_JJ site_NN '_POS affinity_NN (_( Ke_NP )_) of_IN 12.36_CD +-_NN 1.12_CD x_SYM 10-8_CD M-1_NP ,_, which_WDT begin_VBP to_TO decrease_VB when_WRB approximately_RB 1.48_CD %_NN of_IN total_JJ receptor_NN sites_NNS was_VBD occupied_VBN ._SENT With_IN increasing_VBG occupancy_NN of_IN the_DT receptor_NN sites_NNS by_IN 125-I-insulin_NP ,_, the_DT average_JJ receptor_NN affinity_NN progressively_RB decreased_VBD to_TO the_DT '_'' filled_VBN site_NN '_POS affinity_NN (_( Kf_NP )_) of_IN 5.23_CD +-_NN 0.46_CD x_SYM 10-8_CD M-1_NP ,_, when_WRB 71.02_CD %_NN of_IN available_JJ receptor_NN sites_NNS were_VBD occupied_VBN ._SENT The_DT comparable_JJ values_NNS of_IN Ke_NP and_CC Kf_NP for_IN mononuclear_JJ leucocytes_NNS of_IN dogs_NNS administered_VBN with_IN DMSO_NP were_VBD 11.25_CD +-_NN 0.8_CD x_SYM 10-8_CD M-1_JJ (_( 2.00_CD %_NN receptor_NN occupancy_NN )_) and_CC 5.03_CD +-_NN 0.45_CD x_SYM 10-8_CD M-1_JJ (_( 70.01_CD %_NN receptor_NN occupancy_NN )_) respectively_RB ._SENT The_DT comparable_JJ values_NNS of_IN Ke_NP and_CC Kf_NP for_IN mononuclear_JJ leucocytes_NNS of_IN dogs_NNS treated_VBN with_IN 20_CD mg/kg_NN of_IN SNAP_NP were_VBD 9.64_CD +-_NN 0.11_CD x_SYM 10-8_CD M-1_JJ (_( 2.16_CD %_NN receptor_NN occupancy_NN )_) and_CC 4.80_CD +-_NN 0.85_CD x_SYM 10-8_CD M-1_JJ (_( 66.41_CD %_NN receptor_NN occupancy_NN )_) respectively_RB (_( P_NN <_0.05). 0.05_CD )_) ._SENT The_DT Ke_NP value_NN of_IN the_DT insulin_NN receptor_NN for_IN erythrocytes_NNS from_IN dogs_NNS administered_VBN with_IN DMSO_NP was_VBD 8.70_CD +-_NN 0.68_CD x_SYM 10-8_CD M-1_JJ when_WRB 3.11_CD %_NN of_IN available_JJ receptor_NN sites_NNS were_VBD occupied_VBN ._SENT The_DT calculated_JJ mean_JJ value_NN for_IN Kf_NP for_IN the_DT captopril-treated_JJ controls_NNS was_VBD 4.92_CD +-_NN 0.43_CD x_SYM 10-8_CD M-1_NN at_IN an_DT occupancy_NN of_IN 70.72_CD %_NN compared_VBN with_IN 4.53_CD +-_NN 0.57_CD x_SYM 10-8_CD M-1_NN at_IN an_DT occupancy_NN of_IN 78.30_CD %_NN for_IN dogs_NNS treated_VBN with_IN SNAP_NP ._SENT The_DT calculated_JJ mean_JJ value_NN for_IN Kf_NP for_IN dogs_NNS treated_VBN with_IN DMSO_NP was_VBD 4.84_CD +-_NN 0.20_CD x_SYM 10-8_CD M-1_NN at_IN an_DT occupancy_NN level_NN of_IN 71.5_CD %_NN ._SENT The_DT mean_JJ differences_NNS between_IN empty_JJ and_CC filled_VBN site_NN affinities_NNS of_IN the_DT insulin_NN receptor_NN on_IN the_DT erythrocyte_NN cell_NN membrane_NN of_IN captopril-treated_JJ controls_NNS and_CC SNAP-treated_JJ dogs_NNS or_CC between_IN the_DT values_NNS of_IN DMSO-treated_NP and_CC SNAP-treated_NP dogs_NNS were_VBD not_RB statistically_RB significant_JJ (_( P_NN >_SYM 0.05_CD )_) ._SENT On_IN administration_NN of_IN SNAP_NP ,_, a_DT decrease_NN in_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS on_IN the_DT cell_NN membrane_NN on_IN mononuclear_JJ leucocytes_NNS was_VBD observed_VBN in_IN the_DT dogs_NNS ._SENT There_EX was_VBD a_DT 55_CD %_NN decrease_NN in_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS per_IN cell_NN of_IN dogs_NNS treated_VBN with_IN SNAP_NP (_( 11.90_CD +-_NN 1.57_CD x_NN 104_LS )_) compared_VBN with_IN that_DT of_IN mononuclear_JJ leucocytes_NNS for_IN captopril-treated_JJ controls_NNS (_( 22.10_CD +-_NN 1.81_CD x_SYM 104_CD )_) at_IN the_DT 1.5-h_NP time_NN point_NN ._SENT The_DT number_NN of_IN insulin_NN receptor_NN sites_NNS per_IN cell_NN in_IN dogs_NNS treated_VBN administered_VBN with_IN DMSO_NP is_VBZ 21.20_CD +-_NN 1.25_CD x_SYM 104_CD ._SENT The_DT decrement_NN in_IN the_DT insulin_NN receptor_NN sites_NNS per_IN cell_NN between_IN SNAP-treated_JJ and_CC captopril-treated_JJ dogs_NNS was_VBD statistically_RB significant_JJ [_SYM P_NN =_SYM 0.003_CD ,_, Figure_NN ]_SYM ._SENT Figure_NP 7_CD |_SYM Bar_NN graph_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS on_IN the_DT cell_NN membranes_NNS of_IN mononuclear_JJ leucocytes_NNS ._SENT Bar_NN graph_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS on_IN the_DT cell_NN membranes_NNS of_IN mononuclear_JJ leucocytes_NNS ._SENT Statistical_JJ significant_JJ differences_NNS are_VBP indicated_VBN by_IN *P_NP <_SYM 0.05_CD and_CC **P_NNS <_SYM 0.01_CD ._SENT Figure_NN showed_VBD that_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS on_IN the_DT cell_NN membrane_NN of_IN erythrocytes_NNS for_IN SNAP-treated_JJ dogs_NNS was_VBD appreciably_RB less_JJR than_IN those_DT of_IN captopril-treated_JJ dogs_NNS at_IN the_DT 1.5-h_NP time_NN point_NN ._SENT The_DT calculated_JJ insulin_NN receptor_NN sites_NNS per_IN cell_NN for_IN dogs_NNS treated_VBN with_IN captopril_NP and_CC DMSO_NP was_VBD 92_CD +-_NN 6_CD and_CC 89_CD +-_NN 6_CD respectively_RB ,_, compared_VBN with_IN 60_CD +-_NN 4_CD insulin_NN receptor_NN sites_NNS per_IN cell_NN in_IN dogs_NNS treated_VBN with_IN SNAP_NP at_IN the_DT 1.5-h_NP time_NN point_NN (_( P_NN =_SYM 0.285_CD )_) ._SENT Figure_NP 8_CD |_SYM Bar_NN graph_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS ._SENT Bar_NN graph_NN showing_VBG the_DT effect_NN of_IN 20_CD mg/kg_NN of_IN SNAP_NP ,_, 20_CD mg/kg_NN of_IN captopril_NP and_CC 2_CD ml_NN of_IN DMSO_NP on_IN the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS ._SENT This_DT study_NN is_VBZ a_DT sequel_NN to_TO a_DT previous_JJ study_NN by_IN McGrowder_NP et_FW al._FW which_WDT found_VBD that_IN SNAP-treated_NP dogs_NNS displayed_VBD postprandial_JJ hyperglycaemia_NN ._SENT Captopril_NP was_VBD used_VBN as_IN the_DT control_NN drug_NN based_VBN on_IN results_NNS from_IN a_DT study_NN conducted_VBN by_IN Winocour_NP et_FW al._FW which_WDT found_VBD that_DT low-dose_NN therapy_NN had_VBD no_DT significant_JJ effect_NN on_IN blood_NN glucose_NN control_NN in_IN hypertensive_JJ insulin-treated_JJ diabetic_JJ individuals_NNS and_CC that_IN it_PP lowers_VBZ blood_NN pressure_NN by_IN a_DT mechanism_NN which_WDT is_VBZ different_JJ from_IN SNAP_NP ._SENT The_DT study_NN by_IN McGrowder_NP et_FW al._FW also_RB reported_VBD that_IN SNAP_NP at_IN 20_CD mg/kg_NN caused_VBD significant_JJ reduction_NN of_IN the_DT haemodynamic_JJ parameter_NN ,_, mean_JJ arterial_JJ pressure_NN and_CC a_DT significant_JJ increase_NN in_IN heart_NN rate_NN via_IN the_DT release_NN of_IN nitric_JJ oxide_NN ._SENT Captopril_NP at_IN a_DT dose_NN of_IN 20_CD mg/kg_NN had_VBD less_JJR of_IN an_DT effect_NN on_IN both_DT mean_JJ arterial_JJ and_CC heart_NN rate_NN ._SENT The_DT mean_JJ arterial_JJ blood_NN pressure-lowering_VBG effect_NN of_IN captopril_NP (_( an_DT angiotensin_NP converting_VBG enzyme_NN inhibitor_NN )_) is_VBZ related_VBN to_TO a_DT reduction_NN in_IN the_DT peripheral_JJ arterial_JJ vascular_JJ resistance_NN ._SENT The_DT hypotensive_JJ response_NN to_TO captopril_NP is_VBZ accompanied_VBN by_IN a_DT decrease_NN in_IN plasma_NN aldosterone_NN and_CC angiotensin_NP II_NP levels_NNS and_CC an_DT increase_NN in_IN plasma_NN renin_NN levels_NNS ._SENT In_IN response_NN to_TO the_DT decrease_NN in_IN heart_NN rate_NN ,_, there_EX is_VBZ an_DT increase_NN in_IN heart_NN rate_NN through_IN the_DT baroreflex_NN ._SENT Insulin_NN resistance_NN is_VBZ a_DT common_JJ pathological_JJ finding_NN in_IN patients_NNS with_IN impaired_JJ glucose_NN tolerance_NN as_IN well_RB as_RB in_IN subjects_NNS with_IN type_NN II_NP diabetes_NN ._SENT Our_PP$ results_NNS have_VBP shown_VBN that_IN the_DT impaired_JJ glucose_NN tolerance_NN observed_VBN in_IN dogs_NNS treated_VBN with_IN SNAP_NP is_VBZ due_JJ to_TO decreased_VBN insulin_NN binding_VBG to_TO receptors_NNS ._SENT This_DT receptor_NN defect_NN is_VBZ due_JJ to_TO a_DT modulation_NN of_IN the_DT receptor_NN affinity_NN and_CC receptor_NN binding_VBG sites_NNS which_WDT appears_VBZ to_TO effect_VB physiologic_JJ changes_NNS in_IN insulin_NN binding_NN ._SENT Analysis_NN of_IN the_DT data_NNS clearly_RB demonstrated_VBD that_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS isolated_VBN from_IN dogs_NNS acutely_RB treated_VBN with_IN 20_CD mg/kg_NN of_IN SNAP_NP have_VBP decreased_VBN ability_NN to_TO bind_VB insulin_NN ._SENT Decreased_VBN binding_NN was_VBD highly_RB significant_JJ at_IN low_JJ unlabelled_JJ insulin_NN concentrations_NNS ,_, i.e._FW low_JJ occupancy_NN levels_NNS ._SENT Kinetic_JJ analysis_NN of_IN the_DT data_NNS demonstrated_VBD that_IN the_DT decreased_VBN binding_NN of_IN insulin_NN to_TO its_PP$ receptor_NN on_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS was_VBD attributed_VBN primarily_RB to_TO a_DT significant_JJ decrease_NN in_IN the_DT number_NN of_IN insulin_NN receptors_NNS sites_NNS per_IN cell_NN ,_, and_CC secondarily_RB to_TO a_DT reduction_NN in_IN the_DT average_JJ affinity_NN of_IN the_DT receptor_NN for_IN insulin_NN ._SENT Using_VBG the_DT Scatchard_NP method_NN of_IN analysis_NN ,_, graphs_NNS of_IN B/F_NP vs_NP [_SYM B_NN ]_SYM for_IN both_DT mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS [_SYM Figure_NP and_CC Figure_NP ]_SYM yielded_VBN curvilinear_JJ plots_NNS with_IN upward_JJ concavity_NN ._SENT These_DT results_NNS suggest_VBP that_IN the_DT mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS from_IN the_DT dogs_NNS used_VBN in_IN this_DT study_NN have_VBP similar_JJ binding_JJ kinetics_NNS as_IN those_DT expressed_VBN in_IN the_DT literature_NN for_IN lymphocytes_NNS ,_, mononuclear_JJ leucocytes_NNS ,_, erythrocytes_NNS and_CC the_DT insulin_NN target_NN tissues_NNS ._SENT The_DT data_NNS in_IN Figures_NNS and_CC clearly_RB demonstrate_VB that_DT insulin_NN binding_NN is_VBZ decreased_VBN at_IN lower_JJR non-radioactive_JJ insulin_NN concentrations_NNS ,_, but_CC the_DT curves_NNS converge_VBP at_IN the_DT higher_JJR non-radioactive_JJ insulin_NN levels_NNS ._SENT This_DT pattern_NN suggests_VBZ a_DT change_NN in_IN receptor_NN affinity_NN ._SENT The_DT decrease_NN in_IN insulin_NN binding_NN attributed_VBD by_IN a_DT decrease_NN in_IN receptor_NN affinity_NN was_VBD confirmed_VBN by_IN the_DT decrease_NN in_IN the_DT average_JJ affinity_NN (_( K_NP )_) for_IN both_DT mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS ._SENT To_TO investigate_VB whether_IN the_DT decrease_NN in_IN insulin_NN binding_NN was_VBD attributed_VBN to_TO a_DT decrease_NN in_IN the_DT number_NN of_IN receptor_NN sites_NNS per_IN cell_NN ,_, the_DT Scatchard_NP plot_NN for_IN the_DT data_NNS was_VBD analyzed_VBN ._SENT Using_VBG this_DT method_NN of_IN analysis_NN ,_, the_DT x-intercept_NN represents_VBZ the_DT number_NN of_IN insulin_NN receptor_NN sites_NNS per_IN cell_NN ._SENT Calculations_NNS revealed_VBD that_IN there_EX was_VBD a_DT 35_CD %_NN decrease_NN in_IN the_DT number_NN of_IN receptor_NN sites_NNS per_IN erythrocyte_NN in_IN SNAP-treated_JJ dogs_NNS compared_VBN with_IN captopril-treated_JJ controls_NNS ._SENT There_EX was_VBD a_DT significant_JJ 55_CD %_NN decrease_NN in_IN the_DT number_NN of_IN receptor_NN sites_NNS per_IN mononuclear_JJ leucocyte_NN from_IN SNAP-treated_JJ dogs_NNS ._SENT Therefore_RB ,_, the_DT decrease_NN in_IN insulin_NN binding_VBG by_IN the_DT acute_JJ effects_NNS of_IN SNAP_NP is_VBZ primarily_RB as_IN a_DT result_NN of_IN a_DT decrease_NN in_IN the_DT number_NN of_IN receptor_NN sites_NNS per_IN cell_NN ._SENT The_DT cooperative_JJ interactions_NNS among_IN receptor_NN sites_NNS can_MD be_VB explained_VBN in_IN terms_NNS of_IN the_NP '_POS negative_JJ cooperativity_NN '_POS model_NN ._SENT Negative_JJ cooperativity_NN is_VBZ a_DT frequent_JJ occurrence_NN in_IN hormone-receptor_NN systems_NNS in_IN which_WDT there_EX are_VBP site-site_NN interactions_NNS ,_, resulting_VBG in_IN a_DT decrease_NN in_IN the_DT apparent_JJ affinity_NN of_IN receptor_NN for_IN insulin_NN when_WRB fractional_JJ saturation_NN of_IN the_DT receptor_NN increases_NNS ._SENT According_VBG to_TO this_DT model_NN and_CC calculation_NN of_IN the_DT number_NN of_IN receptor_NN sites_NNS using_VBG Scatchard_NP analysis_NN ,_, the_DT decreased_VBN insulin_NN binding_VBG observed_JJ is_VBZ primarily_RB due_JJ to_TO a_DT decrease_NN in_IN the_DT number_NN of_IN receptor_NN sites_NNS ._SENT It_PP can_MD be_VB suggested_VBN that_RB that_IN the_DT lower_JJR number_NN of_IN receptor_NN sites_NNS per_IN cell_NN in_IN dogs_NNS treated_VBN with_IN SNAP_NP ,_, could_MD be_VB the_DT result_NN of_IN primary_JJ alteration_NN in_IN the_DT receptor_NN or_CC may_MD be_VB secondary_JJ to_TO some_DT other_JJ alteration_NN in_IN the_DT integrity_NN of_IN the_DT membrane_NN ._SENT The_DT NO_NP released_VBN from_IN SNAP_NP may_MD damage_VB mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS in_IN the_DT short_JJ term_NN with_IN direct_JJ effects_NNS on_IN membrane_NN structure_NN ,_, membrane_NN fluidity_NN ,_, cross-linking_NN and_CC function_NN ._SENT The_DT molecular_JJ nature_NN and_CC site-site_NN interactions_NNS of_IN the_DT receptor_NN sites_NNS may_MD include_VB mechanisms_NNS such_JJ as_IN intra-molecular_JJ changes_NNS in_IN tertiary_JJ or_CC quaternary_JJ structure_NN of_IN the_DT receptor_NN ,_, association_NN and_CC dissociation_NN of_IN the_DT receptor_NN molecules_NNS ,_, clustering_VBG of_IN receptors_NNS in_IN the_DT membrane_NN or_CC phase_NN transitions_NNS in_IN the_DT membrane_NN itself_PP ._SENT These_DT changes_NNS in_IN membrane_NN integrity_NN could_MD be_VB responsible_JJ for_IN the_DT decreased_VBN number_NN of_IN receptor_NN sites_NNS per_IN cell_NN ._SENT The_DT resulting_VBG membrane_NN dysfunction_NN can_MD impair_VB transport_NN of_IN glucose_NN across_IN the_DT cell_NN membrane_NN resulting_VBG in_IN the_DT observed_JJ hyperglycaemia_NN ._SENT The_DT contributing_VBG effect_NN of_IN any_DT alteration_NN in_IN receptor_NN affinity_NN was_VBD evaluated_VBN by_IN plotting_VBG the_DT data_NNS on_IN an_DT average_JJ affinity_NN graph_NN as_IN described_VBN by_IN De_NP Meyts_NP and_CC Roth_NP ._SENT There_EX was_VBD a_DT significant_JJ 22_CD percent_NN decrease_NN in_IN the_DT empty_JJ site_NN affinity_NN for_IN mononuclear_JJ leucocytes_NNS ,_, supporting_VBG the_DT concept_NN that_IN there_EX can_MD be_VB alterations_NNS in_IN both_DT receptor_NN affinity_NN and_CC receptor_NN sites_NNS ,_, both_CC contributing_VBG to_TO the_DT decreased_VBN insulin_NN binding_NN ._SENT Some_DT of_IN the_DT insulin_NN receptor_NN on_IN the_DT cell_NN membranes_NNS of_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS from_IN dogs_NNS treated_VBN with_IN SNAP_NP may_MD be_VB affected_VBN by_IN the_DT cytotoxic_JJ effect_NN of_IN NO_NP and_CC may_MD become_VB desensitized_VBN ._SENT Desensitization_NN is_VBZ associated_VBN with_IN a_DT total_JJ lack_NN of_IN insulin_NN effect_NN despite_IN remaining_VBG insulin_NN receptors_NNS ._SENT Several_JJ possibilities_NNS exist_VBP to_TO explain_VB the_DT mechanism_NN of_IN changing_VBG receptor_NN affinity_NN and_CC desensitization_NN ._SENT Firstly_RB ,_, fluidity_NN may_MD be_VB an_DT important_JJ factor_NN in_IN modulating_VBG insulin_NN binding_NN and_CC action_NN ._SENT Secondly_RB ,_, the_DT insulin_NN receptor_NN may_MD be_VB covalently_RB associated_VBN with_IN another_DT protein_NN that_WDT modulates_VBZ receptor_NN affinity_NN ._SENT It_PP is_VBZ therefore_RB a_DT possibility_NN that_IN NO_NP released_VBN from_IN SNAP_NP may_MD alter_VB the_DT interaction_NN of_IN insulin_NN with_IN its_PP$ receptors_NNS ,_, thus_RB affecting_VBG the_DT ability_NN of_IN insulin_NN to_TO differentially_RB regulates_VBZ its_PP$ receptor_NN and_CC this_DT regulator_NN protein_NN ._SENT Nitric_JJ oxide_NN may_MD also_RB affect_VB the_DT formation_NN of_IN the_DT insulin_NN receptor_NN complex_NN ._SENT A_DT third_JJ possibility_NN is_VBZ that_IN the_DT receptor_NN undergoes_VBZ some_DT form_NN of_IN post-translational_JJ modification_NN that_WDT alters_VBZ binding_JJ and_CC signal_JJ transmission_NN properties_NNS ._SENT The_DT post-translational_JJ modification_NN could_MD involve_VB a_DT change_NN in_IN the_DT redox_NN state_NN of_IN the_DT receptor_NN ._SENT The_DT insulin_NN receptor_NN is_VBZ composed_VBN of_IN major_JJ sub-units_NNS linked_VBN by_IN disulfide_NN bonds_NNS to_TO various_JJ oligomeric_JJ forms_NNS ._SENT Reduction_NN of_IN the_DT oxidized_VBN forms_NNS of_IN the_DT receptor_NN could_MD modify_VB the_DT affinity_NN of_IN insulin_NN ._SENT Both_CC circulating_VBG erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS exhibit_NN insulin_NN receptors_NNS ._SENT The_DT most_RBS remarkable_JJ difference_NN between_IN these_DT two_CD cell_NN types_NNS is_VBZ the_DT age_NN dependence_NN of_IN the_DT insulin_NN receptor_NN on_IN erythrocytes_NNS ._SENT Clearly_RB major_JJ perturbations_NNS in_IN the_DT mean_JJ cell_NN age_NN of_IN an_DT erythrocyte_NN preparation_NN will_MD have_VB some_DT effect_NN on_IN insulin_NN binding_NN ._SENT Therefore_RB there_EX is_VBZ more_JJR variability_NN in_IN insulin_NN binding_VBG to_TO erythrocytes_NNS than_IN mononuclear_JJ leucocytes_NNS at_IN the_DT limiting_VBG ,_, low_JJ bound/free_JJ ratios_NNS of_IN 125-I-insulin_NP ._SENT This_DT variability_NN affects_VBZ the_DT affinity_NN profiles_NNS derived_VBN from_IN this_DT data_NNS ._SENT The_DT advantage_NN of_IN using_VBG these_DT circulating_VBG blood_NN cells_NNS for_IN investigating_VBG the_DT receptor_NN status_NN in_IN human_JJ and_CC animals_NNS is_VBZ that_IN they_PP are_VBP more_RBR easily_RB accessible_JJ than_IN cells_NNS of_IN primary_JJ insulin_NN target_NN organs_NNS ,_, such_JJ as_IN adipocytes_NNS and_CC muscles_NNS ._SENT It_PP has_VBZ been_VBN found_VBN that_IN the_DT characteristic_NN of_IN insulin_NN binding_VBG to_TO human_JJ adipocytes_NNS (_( including_VBG affinity_NN constants_NNS for_IN the_DT binding_JJ reaction_NN )_) were_VBD similar_JJ to_TO the_DT characteristics_NNS of_IN insulin_NN binding_VBG to_TO mononuclear_JJ leucocytes_NNS in_IN obese_JJ subjects_NNS ._SENT Other_JJ studies_NNS have_VBP also_RB confirmed_VBN that_IN changes_NNS in_IN insulin_NN receptors_NNS of_IN mononuclear_JJ leucocytes_NNS seem_VBP to_TO mirror_VB the_DT events_NNS of_IN more_JJR traditional_JJ insulin_NN target_NN tissues_NNS ._SENT Therefore_RB mononuclear_JJ leucocytes_NNS represents_VBZ a_DT more_RBR uniform_JJ population_NN of_IN cells_NNS capable_JJ of_IN same_JJ receptor-mediated_JJ function_NN as_IN adipocytes_NNS ,_, providing_VBG a_DT clearer_JJR reflection_NN of_IN the_DT insulin_NN receptor_NN status_NN in_IN target_NN tissues_NNS ._SENT The_DT main_JJ objective_NN of_IN the_DT study_NN was_VBD to_TO evaluate_VB any_DT binding_JJ abnormalities_NNS in_IN dogs_NNS with_IN impaired_JJ glucose_NN tolerance_NN as_IN a_DT result_NN of_IN treatment_NN with_IN the_DT nitric_JJ oxide_NN donor_NN ,_, S-nitroso-N-acetylpenicillamine_NP ._SENT This_DT result_NN is_VBZ useful_JJ in_IN elucidating_VBG the_DT possible_JJ diabetogenicity_NN of_IN nitric_JJ oxide_NN ._SENT Whether_IN or_CC not_RB NO_NP plays_VBZ a_DT role_NN in_IN the_DT inhibition_NN of_IN insulin_NN action_NN is_VBZ presently_RB under_IN investigation_NN in_IN our_PP$ laboratory_NN ._SENT We_PP will_MD examine_VB some_DT physiological_JJ assessment_NN of_IN the_DT cells_NNS and_CC measurement_NN of_IN post-receptor_NN signaling_VBG such_JJ as_IN tyrosine_NN kinase_NN activity_NN ,_, insulin_NN receptor_NN substrate-1_NN (_( IRS-1_JJ )_) phosphorylation_NN ,_, and_CC phosphotidylinositol_NN 3-kinase_NN activity_NN ._SENT In_IN summary_NN ,_, the_DT present_JJ report_NN demonstrated_VBD that_IN impaired_JJ glucose_NN tolerance_NN observed_VBD in_IN SNAP-treated_NP is_VBZ associated_VBN with_IN a_DT decrease_NN in_IN insulin_NN receptor_NN binding_NN ._SENT The_DT mechanism_NN of_IN decreased_VBN insulin_NN binding_NN was_VBD due_JJ primarily_RB to_TO a_DT significant_JJ reduction_NN in_IN the_DT number_NN of_IN receptor_NN sites_NNS per_IN cell_NN and_CC to_TO a_DT lesser_JJR extent_NN ,_, a_DT reduction_NN in_IN the_DT average_JJ receptor_NN affinity_NN ._SENT These_DT findings_NNS for_IN the_DT first_JJ time_NN suggest_VBP a_DT novel_JJ role_NN of_IN NO_NP as_IN a_DT modulator_NN of_IN insulin_NN binding_NN ._SENT Animals_NNS --_: Experimental_JJ design_NN |_SYM The_DT protocol_NN was_VBD conducted_VBN in_IN accordance_NN with_IN the_DT guidelines_NNS of_IN the_DT University_NP of_IN the_DT West_NP Indies_NP Animal_NP Committee_NP ._SENT Eighteen_CD normal_JJ Mongrel_NP dogs_NNS (_( 9_CD males_NNS and_CC 9_CD females_NNS )_) of_IN 2_CD --_: 3_CD years_NNS ,_, with_IN average_JJ weight_NN of_IN 11_CD +-_NN 0.4_CD kg_NN were_VBD obtained_VBN from_IN the_DT Pre-Clinical_NP Animal_NP House_NP of_IN the_DT Department_NP of_IN Basic_NP Medical_NP Sciences_NPS ,_, University_NP of_IN the_DT West_NP Indies_NP ._SENT The_DT animals_NNS were_VBD maintained_VBN in_IN the_DT animal_JJ house_NN under_IN the_DT supervision_NN of_IN attendants_NNS and_CC a_DT veterinary_JJ consultant_NN ._SENT Dogs_NNS were_VBD fed_VBN on_IN a_DT diet_NN of_IN Purina_NP Laboratory_NP Chow_NP (_( Purina_NP ,_, St._NP Louis_NP MO_NP ._SENT U.S.A._NP )_) and_CC water_NN administered_VBN ad_NN libitum_NN ._SENT The_DT dogs_NNS were_VBD divided_VBN into_IN three_CD groups_NNS ,_, test_NN and_CC controls_NNS ._SENT An_DT oral_JJ glucose_NN tolerance_NN test_NN was_VBD performed_VBN on_IN each_DT dog_NN ._SENT Briefly_RB ,_, after_IN an_DT 18-h_NN fast_RB ,_, dogs_NNS were_VBD anaesthetized_VBN with_IN sodium_NN pentabarbital_NN (_( 30_CD mg/kg_NN i.v._NN )_) ._SENT Subsequently_RB ,_, the_DT fasting_VBG blood_NN sample_NN was_VBD taken_VBN and_CC in_IN control_NN experiments_NNS 20_CD mg/kg_NN body_NN weight_NN of_IN captopril_NP (_( Sigma_NP Chemicals_NPS Co._NP Ltd._NP St._NP Louis_NP MO_NP ._SENT USA_NP )_) dissolved_VBD in_IN water_NN was_VBD administered_VBN intravenously_RB ._SENT In_IN test_NN experiments_NNS ,_, S-nitroso-N-Acetylpenicillamine_NP (_( SNAP_NP ;_: Sigma_NP Chemicals_NPS Co._NP Ltd._NP St._NP Louis_NP MO_NP ._SENT USA_NP )_) was_VBD dissolved_VBN in_IN 2_CD ml_NN of_IN dimethyl_NN sulphoxide_NN (_( DMSO_NP at_IN a_DT concentration_NN of_IN 0.0014_CD mol/L_NN )_) and_CC administered_VBN at_IN 20_CD mg/kg_NN body_NN weight_NN to_TO the_DT dogs_NNS ._SENT Additional_JJ blood_NN samples_NNS were_VBD collected_VBN 1.5-h_NN after_IN administration_NN of_IN a_DT glucose_NN load_NN of_IN 1.75_CD g/kg_NN body_NN weight_NN ._SENT In_IN a_DT previous_JJ study_NN by_IN McGrowder_NP et_FW al._FW pilot_NN experiments_NNS were_VBD carried_VBN out_RP where_WRB a_DT low_JJ dose_NN of_IN 5_CD mg/kg_NN body_NN weight_NN of_IN SNAP_NP or_CC captopril_NP was_VBD first_RB administered_VBN and_CC its_PP$ effect_NN on_IN the_DT blood_NN glucose_NN observed_VBN during_IN oral_JJ glucose_NN tolerance_NN test_NN ._SENT Subsequent_JJ experiments_NNS involved_VBD increasing_VBG the_DT doses_NNS of_IN SNAP_NP and_CC captopril_NP ,_, based_VBN on_IN the_DT effect_NN of_IN the_DT previous_JJ dose_NN on_IN the_DT blood_NN glucose_NN levels_NNS ._SENT The_DT result_NN showed_VBD that_IN SNAP_NP at_IN 20_CD mg/kg_NN had_VBD a_DT significant_JJ effect_NN on_IN blood_NN glucose_NN levels_NNS especially_RB at_IN the_DT 1.5-h_NP time_NN point_NN ,_, while_IN a_DT similar_JJ dose_NN of_IN captopril_NP had_VBD little_JJ or_CC no_DT effect_NN ._SENT In_IN this_DT study_NN blood_NN samples_NNS were_VBD taken_VBN at_IN the_DT 1.5-h_NP time_NN point_NN ._SENT Each_DT sample_NN was_VBD collected_VBN in_IN an_DT EDTA_NP tube_NN and_CC immediately_RB placed_VBN on_IN ice_NN for_IN subsequent_JJ biochemical_JJ analysis_NN ._SENT Preparation_NN of_IN purified_VBN erythrocytes_NNS |_SYM The_DT mononuclear_JJ leucocytes_NNS and_CC erythrocytes_NNS were_VBD separated_VBN using_VBG a_DT Percoll_NP density_NN gradient_NN ._SENT Mononuclear_JJ leucocytes_NNS were_VBD separated_VBN from_IN the_DT erythrocytes_NNS by_IN the_DT use_NN of_IN pasteur_NN pipettes_NNS ._SENT The_DT erythrocytes_NNS receptor_NN assay_NN was_VBD performed_VBN according_VBG to_TO a_DT modification_NN of_IN the_DT method_NN by_IN Ghambir_NP et_CC al_NP ._SENT The_DT erythrocytes_NNS were_VBD washed_VBN three_CD times_NNS by_IN centrifugation_NN (_( 4C_NP ,_, 4500_CD rpm_NN )_) in_IN 10_CD ml_NN of_IN buffer_NN G_NN containing_VBG 1_CD %_NN human_JJ serum_NN albumin_NN ,_, (_( pH_NN 7.8_CD )_) for_IN 10_CD minutes_NNS ._SENT On_IN each_DT occasion_NN ,_, the_DT supernatant_JJ was_VBD removed_VBN and_CC the_DT cells_NNS re-suspended_VBN in_IN buffer_NN G_NN ,_, and_CC re-spun_NN ._SENT After_IN the_DT final_JJ wash_NN of_IN the_DT cells_NNS ,_, the_DT supernatant_JJ was_VBD removed_VBN and_CC the_DT cells_NNS were_VBD left_VBN in_IN 4_CD ml_NN of_IN buffer_NN G_NN containing_VBG 1_CD %_NN human_JJ serum_NN albumin_NN ._SENT This_DT suspension_NN contained_VBN 4_CD --_: 6_CD x_SYM 109_CD cells/ml_NN ._SENT Preparation_NN of_IN purified_VBN mononuclear_JJ leucocytes_NNS |_SYM Mononuclear_JJ leucocytes_NNS were_VBD re-suspended_VBN in_IN 4_CD ml_NN of_IN cold_JJ Buffer_NP M_NP and_CC centrifuged_VBN at_IN 1100_CD rpm_NN for_IN 10_CD minutes_NNS at_IN 4C_JJ ._SENT This_DT was_VBD repeated_VBN three_CD times_NNS ,_, and_CC on_IN each_DT occasion_NN the_DT supernatant_JJ was_VBD removed_VBN and_CC the_DT cells_NNS re-suspended_VBN in_IN buffer_NN M._NP After_IN the_DT final_JJ washing_NN ,_, the_DT cells_NNS were_VBD left_VBN in_IN 1_CD %_NN human_JJ serum_NN albumin_NN (_( approximately_RB 2_CD ml_NN )_) in_IN buffer_NN M._NP The_DT mononuclear_JJ leucocytes_NNS had_VBD a_DT concentration_NN of_IN 1.70_CD --_: 2.00_CD x_SYM 107_CD cells/ml_NN ._SENT Binding_VBG of_IN 125-I_NP to_TO mononuclear_JJ cells_NNS and_CC erythrocyte_NN cells_NNS |_SYM Receptor_JJ binding_NN were_VBD evaluated_VBN by_IN the_DT use_NN of_IN the_DT Scatchard_NP analysis_NN of_IN competitive-inhibition_NN curves_NNS ,_, which_WDT is_VBZ a_DT modification_NN of_IN the_DT original_JJ technique_NN described_VBN by_IN Gambir_NP et_CC al_NP ._SENT Lyophilized_VBN unlabelled_JJ non-radioactive_JJ insulin_NN (_( 10_CD mg_NN ;_: Sigma_NP porcine_JJ ,_, 23.5_CD U/mg_NP ,_, Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, MO_NP USA_NP )_) was_VBD reconstituted_VBN in_IN 0.1_CD M_NP HCl_NP (_( 10_CD ml_NN )_) and_CC 100_CD mul_NN quantities_NNS were_VBD dispensed_VBN and_CC stored_VBN at_IN -70C_NN until_IN required_VBN ._SENT Monoiodinated_NP A14_NP [_SYM 125-I_NP ]_SYM insulin_NN (_( Amershan_NP ,_, Arlington_NP Heights_NP ,_, IL_NP USA_NP ;_: specific_JJ radioactivity_NN 50_CD muCi_NNS )_) was_VBD dissolved_VBN in_IN deionised_JJ water_NN (_( 500_CD mul_NN )_) and_CC aliquots_NNS of_IN 5_CD mul_NN stored_VBN at_IN -70C_NN until_IN needed_VBN ._SENT One_CD hundred_CD and_CC fifty_CD (_( 150_CD )_) mul_NN aliquots_NNS of_IN the_DT washed_JJ erythrocyte_NN suspension_NN were_VBD added_VBN to_TO a_DT series_NN of_IN Eppendorf_NP tubes_NNS in_IN triplicate_NN ._SENT To_TO each_DT sample_NN tube_NN was_VBD added_VBN ,_, standard_JJ (_( 50_CD mul_NN )_) and_CC 125-I-insulin_NP (_( 50_CD mul_NN )_) and_CC the_DT incubated_VBN for_IN 3_CD hours_NNS ._SENT Similar_JJ experiments_NNS were_VBD carried_VBN out_IN using_VBG mononuclear_JJ leucocytes_NNS ._SENT The_DT mononuclear_JJ leucocyte_NN reaction_NN was_VBD stopped_VBN with_IN cold_JJ buffer_NN M_NN and_CC the_DT tubes_NNS were_VBD centrifuged_VBN at_IN 1100_CD rpm_NN for_IN 2_CD minutes_NNS ._SENT The_DT cells_NNS were_VBD washed_VBN twice_RB ,_, and_CC the_DT radioactivity_NN of_IN the_DT pellet_NN was_VBD determined_VBN using_VBG a_DT Gamma_NP Counter_NP (_( Abbott_NP Auto_NP Logic_NP Gamma_NP Counter_NP )_) ._SENT The_DT erythrocyte_NN reaction_NN was_VBD stopped_VBN by_IN adding_VBG 1_CD ml_NN of_IN cold_JJ saline_NN and_CC centrifuged_VBN at_IN 1100_CD rpm_NN for_IN 1_CD minute_NN ._SENT The_DT supernatant_JJ was_VBD discarded_VBN and_CC 100_CD mul_NN of_IN 40_CD %_NN formalin_NN was_VBD added_VBN to_TO harden_VB the_DT red_JJ cell_NN pellet_NN ._SENT The_DT radioactivity_NN of_IN the_DT pellet_NN was_VBD also_RB determined_VBN using_VBG a_DT Gamma_NP Counter_NP ._SENT The_DT data_NNS was_VBD analyzed_VBN by_IN Scatchard_NP analysis_NN ._SENT The_DT receptor_NN affinity_NN and_CC receptor_NN numbers_NNS were_VBD derived_VBN for_IN the_DT physiological_JJ range_NN of_IN insulin_NN i.e._FW between_IN 0.1_CD and_CC 100_CD ng/ml_NNS ._SENT Specific_JJ insulin_NN binding_VBG (_( SB_NP )_) was_VBD calculated_VBN as_IN the_DT percentage_NN of_IN radioactive_JJ insulin_NN bound_VBN by_IN 4_CD x_NN 109_CD and_CC 2_CD x_SYM 106_CD cells/ml_NN for_IN erythrocytes_NNS and_CC mononuclear_JJ leucocytes_NNS ,_, respectively_RB ._SENT Non-specific_JJ binding_NN was_VBD assessed_VBN by_IN the_DT amount_NN of_IN radioactive_JJ insulin_NN bind_NN in_IN the_DT presence_NN of_IN 100_CD ng/ml_NNS unlabelled_JJ insulin_NN ._SENT Competitive_JJ binding_JJ curves_NNS were_VBD obtained_VBN for_IN each_DT erythrocyte_NN and_CC mononuclear_JJ leucocyte_NN suspension_NN ._SENT From_IN these_DT curves_NNS ,_, the_DT insulin_NN receptor_NN affinity_NN and_CC number_NN of_IN the_DT receptor_NN sites_NNS were_VBD determined_VBN by_IN the_DT Scatchard_NP analysis_NN ._SENT Cell_NN binding_JJ analysis_NN |_SYM The_DT results_NNS of_IN the_DT binding_JJ studies_NNS are_VBP presented_VBN in_IN three_CD ways_NNS :_: (_( 1_LS )_) the_DT percentage_NN binding_VBG of_IN 125-I-insulin_NP as_IN a_DT function_NN of_IN the_DT total_JJ insulin_NN concentration_NN (_( competitive_JJ curve_NN )_) ,_, (_( 2_LS )_) the_DT bound-free_JJ insulin_NN ratio_NN plotted_VBD as_IN a_DT function_NN of_IN the_DT bound_JJ insulin_NN (_( Scatchard_NP plot_NN )_) and_CC ,_, (_( 3_LS )_) the_DT average_JJ affinity_NN profile_NN calculated_VBD according_VBG to_TO the_DT method_NN of_IN De_NP Meyts_NP and_CC Roth_NP ._SENT The_DT total_JJ binding_JJ capacity_NN or_CC concentration_NN of_IN the_DT binding_JJ sites_NNS was_VBD derived_VBN from_IN the_DT point_NN where_WRB th_NN 